The company has secured 506 marketing approvals for its oncology products across 76 countries.
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Darolutamide is developed jointly by Bayer and Orion Corporation
Subscribe To Our Newsletter & Stay Updated
